InterMune

InterMune is a biotechnology company dedicated to the research, development, and commercialization of therapies aimed at treating pulmonary and orphan fibrotic diseases. The company primarily focuses on idiopathic pulmonary fibrosis (IPF), a progressive and serious lung condition. Its flagship product, Pirfenidone, is the first medication approved for IPF globally, marketed in the European Union under the brand name Esbriet®. InterMune is actively conducting a Phase 3 clinical trial to seek regulatory approval for this treatment in the United States. Additionally, the company is engaged in research initiatives to discover targeted small-molecule therapeutics and biomarkers for serious pulmonary and fibrotic diseases. Beyond pulmonology, InterMune also has products approved for treating severe conditions such as malignant osteopetrosis and chronic granulomatous disease, indicating a diverse therapeutic focus.